Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00883116 · ClinicalTrials.gov registry record · Phase 3
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
A Phase 3 study, sponsored by R-Pharm.
- Terminated
- Registry status
- Phase 3
- Development phase
- 551
- Enrollment target
NCT00883116 is a Phase 3 study that was terminated before completion, run by R-Pharm. The registered enrollment target is 551 participants.
The verdict
NCT00883116, a Phase 3 study, was terminated before completion, sponsored by R-Pharm.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 551 participants
- Enrollment target
Study Summary
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed following first-line chemotherapy.
Interventions
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 551 participants |
| Start Date | 2009-08 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00883116
The ClinicalTrials.gov registry entry for NCT00883116 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 551 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Doxorubicin is the first listed.
NCT00883116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00883116 about?
NCT00883116 is a clinical study titled "A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer". The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed follo...
What is the current status of trial NCT00883116?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 551 participants. The study started on 2009-08. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00883116?
The interventions under investigation include: Doxorubicin (DRUG), Paclitaxel (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00883116?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.